Agenus Cancels Conference Call to Discuss the Company’s Minority Cash Holdings at SVB in Light of Government’s SVB Deposit Access Announcement
Agenus has announced the cancellation of its conference call scheduled for March 13, 2023, regarding its minority cash holdings at Silicon Valley Bank (SVB).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Agenus has announced the cancellation of its conference call scheduled for March 13, 2023, regarding its minority cash holdings at Silicon Valley Bank (SVB). This decision follows the government's announcement concerning access to SVB deposits. Agenus is a clinical-stage immuno-oncology company focused on developing therapies that enhance the body's immune response against cancer and infections. The company's approach includes a wide array of antibody therapeutics and adoptive cell therapies. Headquartered in Lexington, MA, Agenus continues to aim for innovative cancer treatment solutions.
Positive
- The company has a robust pipeline of immuno-oncology therapies.
- Agenus invests in combination approaches to enhance cancer immunotherapy.
Negative
- Cancellation of the conference call may signal uncertainty regarding cash positions.
Details
News Market Reaction – AGEN
The recorded move for AGEN in the trading session of this news was +14.00%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call Cancelled
LEXINGTON, Mass., March 12, 2023 (GLOBE NEWSWIRE) -- Agenus (Nasdaq: AGEN), a clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, today announced that it has cancelled its conference call on Monday, March 13th to discuss its minority cash holdings at Silicon Valley Bank (SVB) in light of the government’s SVB deposit access announcement.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), and adjuvants (through its subsidiary SaponiQx). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.
Contact
Agenus Inc.
Zack Armen
Head of Investor Relations
917-362-1370
zack.armen@agenusbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.